Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
AC Immune SA is a clinical-stage biopharmaceutical company focused on precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The company designs, discovers, and develops therapeutic and diagnostic products aimed at prevention, diagnosis, and treatment of these conditions. Its proprietary technology platforms, SupraAntigen and Morphomer, enable the creation of antibodies, small molecules, active immunotherapies, and vaccines targeting a broad range of neurodegenerative disorders. AC Immune SA maintains a diversified pipeline featuring multiple clinical-stage candidates, such as ACI-7104, an anti-α-synuclein active immunotherapy for early Parkinson’s disease, ACI-24 and ACI-35 in pharmaceutical collaborations, and small molecule programs including brain-penetrant NLRP3 inhibitors like ACI-19764 and Tau aggregation inhibitors. The company collaborates with leading global pharmaceutical partners, including Janssen Pharmaceuticals, Takeda, Eli Lilly and Co., and others, to advance its programs. Founded in 2003 and headquartered in Lausanne, Switzerland, AC Immune SA plays a significant role in addressing the growing challenges of neurodegeneration through innovative therapeutic and diagnostic solutions.
CHF 2.45
CHF 0.09 (-3.54%)
EOD Jun 25, 2026 · Twelve Data
The business is unprofitable at the operating level (-1927.32% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 86.9% YoY. Margins deteriorated 1735.5pp alongside, both lines moving the wrong way.
Free cash flow declined 208% versus the prior year, cash generation momentum has weakened. ROIC dropped from -29.36% to -65.10%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
CHF 4M
▼ -86.9% YoY
Net Income (TTM)
-CHF 66M
▼ -38.4% YoY
Op. Margin
-1736.39%
▼ -1735.5pp YoY
ROIC
-65.10%
▼ -35.7pp YoY
Cash Flow & Balance Sheet
FCF (FY)
-CHF 70M
▼ -207.5% YoY
Op. Cash Flow (FY)
-CHF 65M
▼ -199.1% YoY
Net Debt
-CHF 87M
Net Cash Position
Cash & Equiv.
CHF 91M
3Y CAGR: -3.2%
Continue Research
Acimmune SA (ACIU)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Acimmune SA scores 25/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Acimmune SA scores 25 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -1,736.4% operating margin and a -65.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ACIU's valuation and scores 25/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.